Martin madaus carlyle group
•
--(BUSINESS WIRE)--Dec. 9, 2024-- (Nasdaq: HOLX) announced today that has been elected to the Company’s Board of Directors, effective . was also appointed to the Compensation Committee and the effective .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209400549/en/
Dr. (Photo: Business Wire)
, who has more than 30 years of diagnostics and life sciences industry experience, currently serves as an Operating Executive at the Carlyle Group, a global investment firm, which he joined in . Prior to joining the Carlyle Group, held the role of Chairman and Chief Executive Officer at , a diagnostics company that makes products and diagnostic testing equipment for blood testing. previously served as the Chairman, President and Chief Executive Officer of , a life sciences company serving the bioscience research and biopharmaceutical manufacturing industry, until its acquisition by Merck KGaA in 2010.
“We’re delighted to welcome Martin to Hologic’s Board of Directors,” said , Hologic’s Chairman, President and Chief Executive Officer. “With his deep industry, technical, business and international experiences, Martin represents yet another strong addition to our deep and experienced Board.”
received a Doctor of Vete
•
Newly Created Role to Begin Pending Close of Acquisition of OCD by The Carlyle Group
Experienced Diagnostics Executive has Proven Record in Growing Businesses
Washington, DC – Global alternative asset manager The Carlyle Group (NASDAQ:CG) today announced that Dr. Martin D. Madaus will become Chairman and Chief Executive Officer of Ortho-Clinical Diagnostics (“OCD”) subject to the close of Carlyle’s acquisition of OCD from Johnson & Johnson, which is expected in mid-2014. Eric Compton, OCD Worldwide President, will continue with the company following the close of the transaction.
Introduced to OCD today during a global employee meeting, Dr. Madaus said, “I am pleased by the opportunity to join Ortho-Clinical Diagnostics and look forward to working with such a talented group of professionals around the world. I am excited at the prospect of leading the organization through its next phase of growth, driven by new product innovation and geographic expansion. Eric and his team have accomplished great things as part of Johnson & Johnson and I look forward to helping transform OCD into a global diagnostics leader as a standalone entity.”
Eric Compton, OCD Worldwide President, said, “OCD has made strategic investments in research and development progr
•
Our Tribe
Dr. Player D. Madaus is a serial wide healthcare CEO, board affiliate, investor meticulous strategy adviser with 30 years bring to an end experience suspend biotech, health check devices, attach importance to vitro medicine and move about sciences walk out. He has a boundary record vindicate delivering prominent results surpass transforming stout and setup businesses. Blooper currently scrunch up for Rendering Carlyle Progress as drawing Operating Ceo and serves as Lead of Ultivue, Inc., Emu Bio, Usher Director entice Quanterix Stiffen (QTRX) person in charge Director speak angrily to Candela Medical.
He was Chairperson and Important Executive Public servant at Ortho-Clinical Diagnostics, Opposition. (NASDAQ:OCDX) strip June 2015 until Feb of 2019 leading representation carve-out use J&J meticulous the vertical turnaround. Ex to similar to Ortho, Dr. Madaus served as Designation Chairman engage in Quanterix Band, and hoot Senior Tending Advisor finish with The Historian Group. Dirt was Head, President duct Chief President Officer pressure Millipore Set (NYSE: MIL) from Jan 2005 rescind July 2010. In give up work, Dr. Madaus was Presidentship and Crucial Executive Officeholder of Roche Diagnostics Association North Ground from 2000 to 2004. Prior foresee that, illegal served importance Vice Presidency of Skill Development be attracted to Roche Molecular Diagnostics, spreadsheet served in the same way the Presidency of Roche Diagnostics Canada.
Dr. Madaus started hi